While further investigations of the pharmacological effects and molecular mechanisms underlying R7 activity will be required to validate our findings, our results revealed that R7 is a promising chemotherapeutic agent for the treatment of cervical cancer and other PI3K/PTEN/Akt/mTOR signaling-associated tumors. Here, MTOR is linked to cervical carcinoma.